Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
Key facts
- Who runs it
- University of Aarhus
- Where
- Denmark2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 71 people enrolled
- Started
- 1 May 2018
- Ended
- 21 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Prednisolone
- Alfacalcidol
- Record updated
- 24 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Biopsy proven minimal change nephropathy
- If earlier minimal change: No relapse in 5 years, and earlier only treated with prednisolone
- Nephrotic syndrome
- Age more than 18 years
Who cannot take part
- Cancer except from basal cells carcinoma
- Lymphoproliferative disease
- Allergy
- eGFR < 30 ml/min/1,73m2 (CKD-EPI)
- Pregnancy
- No danish language
- No ability to give informed prove
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Traditionally MCN is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. Prednisolone treatment contains numerous side effects and the current dose is empiric. Given the lack of efficacy evidence and the risk associated with the currently accepted treatment regimen there is a need to characterize the outcome in MCN further, and to establish new, and potentially less toxic treatment regimens.
Read full original descriptionShow less
The aim is to examine if treatment with reduced dose of prednisolone in combination with activated vitamin D is as effective as standard high dose prednisolone in achieving remission and preventing relapse in MCN, and if reduced dose prednisolone is associated with fewer side effects compared to standard dose. Furthermore, the study will examine the influence of prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of MCN.
The 2 groups in the trial
- High dose prednisoloneExisting treatment, for comparison
Prednisolone 1 mg/kg/day
Treatment: Prednisolone
- Alfacalcidol and low dose prednisoloneTreatment being tested
Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
Treatment: Prednisolone and Alfacalcidol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D
- Publications
- A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy.Kidney international, 2026
- Interventions for minimal change disease in adults with nephrotic syndrome.The Cochrane database of systematic reviews, 2022
- A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN).Trials, 2021
- Record updated
- 24 January 2025